# EDGAR Filing Document

**Accession Number:** 0001979414
**File Stem:** 0000000000-25-008768
**Filing Date:** 2025-8
**Character Count:** 3079
**Document Hash:** 8e9e26a2ccd374b4dcefbeb1642c86ab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008768.hdr.sgml**: 20260113

**ACCESSION NUMBER**: 0000000000-25-008768

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250819

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NEONC TECHNOLOGIES HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001979414
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 921954864
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-42567

**BUSINESS ADDRESS:**
- **STREET 1:** 23975 PARK SORRENTO
- **STREET 2:** SUITE 205
- **CITY:** CALABASAS
- **STATE:** CA
- **ZIP:** 91302
- **BUSINESS PHONE:** 310 663 7831

**MAIL ADDRESS:**
- **STREET 1:** 23975 PARK SORRENTO
- **STREET 2:** SUITE 205
- **CITY:** CALABASAS
- **STATE:** CA
- **ZIP:** 91302
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001829126-25-006425

## Text-Extract

```

                                                           August 19, 2025

Keithly Garnett
Chief Financial Officer
NeOnc Technologies Holdings, Inc.
23975 Park Sorrento Suite 205
Calabasas, CA. 91302

       Re: NeOnc Technologies Holdings, Inc.
           Form 8-K filed August 18, 2025
           File No. 001-42567
Dear Keithly Garnett:

       We have reviewed your filing and have the following comment.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Form 8-K filed August 18, 2025
Item4.02 - Non-Reliance on Previously Issued Financial Statements or a Related
Audit
Report or Completed Interim Review., page 1

1.     Please revise your disclosure to include a statement of whether the
audit committee, or
       the board of directors in the absence of an audit committee,
       or authorized officer or officers, discussed with the registrant   s
independent
       accountant the matters disclosed in the filing pursuant to Item
4.02(a)(3), or tell us
       where such disclosure was made.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.
 August 19, 2025
Page 2

       Please contact Lynn Dicker at (202) 551-3616 or Kevin Vaughn at (202)
551-3494 if
you have questions regarding comments on the financial statements and related
matters.

                                                         Sincerely,

                                                         Division of
Corporation Finance
                                                         Office of Life
Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._